Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
Brodowicz T, Liegl-Atzwager B, Tresch E, Taieb S, Kramar A, Gruenwald V, Vanseymortier M, Clisant S, Blay JY, Le Cesne A, Penel N. Brodowicz T, et al. Among authors: clisant s. BMC Cancer. 2015 Mar 14;15:127. doi: 10.1186/s12885-015-1143-y. BMC Cancer. 2015. PMID: 25884155 Free PMC article. Clinical Trial.
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe LM, Etienne PL, Mineur L, Clisant S, Phelip JM, Kramar A, Andre T. Adenis A, et al. Among authors: clisant s. BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9. BMC Cancer. 2016. PMID: 27389564 Free PMC article. Clinical Trial.
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Mir O, et al. Among authors: clisant s. Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14. Lancet Oncol. 2016. PMID: 27751846 Clinical Trial.
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N. Bompas E, et al. Among authors: clisant s. Ann Oncol. 2015 Oct;26(10):2168-73. doi: 10.1093/annonc/mdv300. Epub 2015 Jul 22. Ann Oncol. 2015. PMID: 26202596 Free PMC article. Clinical Trial.
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N; French Sarcoma Group (GSF/GETO). Ray-Coquard I, et al. Among authors: clisant s. Oncologist. 2012;17(2):260-6. doi: 10.1634/theoncologist.2011-0237. Epub 2012 Jan 27. Oncologist. 2012. PMID: 22285963 Free PMC article. Clinical Trial.
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, Robin YM, Fournier C, Clisant S, Chaigneau L, Bay JO, Bompas E, Gauthier E, Blay JY, Penel N. Chevreau C, et al. Among authors: clisant s. Cancer. 2013 Jul 15;119(14):2639-44. doi: 10.1002/cncr.28109. Epub 2013 Apr 15. Cancer. 2013. PMID: 23589078 Free article. Clinical Trial.
Regorafenib use as a possible cause of intestinal perforation.
Adenis A, Kotecki N, Decanter G, Clisant S, Penel N. Adenis A, et al. Among authors: clisant s. Acta Oncol. 2013 Nov;52(8):1789-90. doi: 10.3109/0284186X.2013.835070. Epub 2013 Sep 12. Acta Oncol. 2013. PMID: 24024697 No abstract available.
Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S, Saada-Bouzid E, Tresch E, Ryckewaert T, Bompas E, Italiano A, Guillemet C, Peugniez C, Piperno-Neumann S, Thyss A, Maynou C, Clisant S, Penel N; French Sarcoma Group. Taieb S, et al. Among authors: clisant s. Eur J Cancer. 2015 Jan;51(2):202-9. doi: 10.1016/j.ejca.2014.11.008. Epub 2014 Dec 9. Eur J Cancer. 2015. PMID: 25499439
55 results